| For: | Suresh MG, Mohamed S, Geetha HS, Prabhu S, Trivedi N, Ng ZC, Mehta PD, Brar AS, Sohal A, Goyal MK, Hatwal J, Batta A. Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: Pathophysiology, diagnosis, and emerging therapeutic strategies. World J Diabetes 2026; 17(2): 113149 [PMID: 41696109 DOI: 10.4239/wjd.v17.i2.113149] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v17/i2/113149.htm |
| Number | Citing Articles |
| 1 |
Fuliang Li, Hongmei Li, Dulguun Juramt, Kai Kou, Frank Tacke, Lanlan Chen. Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics. BMJ Open Gastroenterology 2026; 13(1) doi: 10.1136/bmjgast-2026-002343
|
| 2 |
Jing Zhou, Nenghan Zhang, Jiajun Li, Xiangqi Qin, Lingqi Kong, Liang Bai, Tuo Han. Glucagon-like peptide 1 receptor agonists in cardiovascular-kidney-metabolic syndrome: a review. Exploration of Endocrine and Metabolic Diseases 2026; 3 doi: 10.37349/eemd.2026.101481
|
| 3 |
Manjeet Kumar Goyal, Juniali Hatwal, Rupak Desai, Tanisha Sehgal, Akash Batta. Glycated hemoglobin and cardiovascular risk in diabetes mellitus: Evolving evidence beyond glycemic control. World Journal of Diabetes 2026; 17(6): 115820 doi: 10.4239/wjd.115820
|
| 4 |
Muneera AlTaweel, Mareyah Alshaikh Husain, Maram Rashid AlSubaiee, Ali Al Qarni, Ibraheem Aldossary. BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia. Current Medical Research and Opinion 2026; 42(5) doi: 10.1080/03007995.2026.2692167
|
| 5 |
Fernanda M. Martínez-Díaz, Elsie A. Jiménez-Cuevas, Mariana M. Ramírez-Mejía, Sarai Gómez-Camacho, Nahum Méndez-Sánchez. The interplay of insulin resistance, glycemic variability, and metabolic dysfunction-associated steatotic liver disease. Exploration of Digestive Diseases 2026; 5 doi: 10.37349/edd.2026.1005115
|
| 6 |
Ruizhe Ren, Siying Ren, Yihan Xu, Xiao Liang, Xiyang Wei. Non-coding RNA networks in metabolic dysfunction-associated steatotic liver disease: Mechanisms and therapeutic perspectives. Liver Research 2026; 10(2) doi: 10.1016/j.livres.2026.05.002
|
| 7 |
Manjeet Kumar Goyal, Juniali Hatwal, Rupak Desai, Tanisha Sehgal, Akash Batta. Do biomarkers matter? Cardiovascular risk stratification in Asian patients with metabolic dysfunction-associated steatotic liver disease in the era of fibrosis-centric assessment. World Journal of Gastroenterology 2026; 32(28): 117181 doi: 10.3748/wjg.117181
|
| 8 |
Andong Li, Meiyu Wu, Yangke Yi, Yongtao He, Chongqing Tan, Xia Luo, Jun Zhang, Xiaomin Wan. Resmetirom for noncirrhotic metabolic dysfunction–associated steatohepatitis with liver fibrosis: establishing a value-based price in China, the UK, France, and Germany. Expert Review of Pharmacoeconomics & Outcomes Research 2026; doi: 10.1080/14737167.2026.2718421
|
| 9 |
Ileana Pantea, Angela Repanovici, Hamza Islam. Tirzepatide in Metabolically Dysfunctional‐Associated Steatohepatitis (MASH): A Bibliometric and Evidence‐Based Review. Journal of Diabetes Research 2026; 2026(1) doi: 10.1155/jdr/1853763
|
| 10 |
Rishi Chowdhary, Manjeet Kumar Goyal, Megh Patel, Rahul Chowdhary, Kirti Arora, Varun Mehta, Akash Batta, Omesh Goyal, Ashita Rukmini Vuthaluru. Incidence, prevalence, and prognostic impact of sarcopenia on hepatic and cardiovascular outcomes in non-cirrhotic metabolic dysfunction–associated steatotic liver disease. Frontiers in Epidemiology 2026; 6 doi: 10.3389/fepid.2026.1779600
|
| 11 |
Nebyu Yonas Shanka, Chavdar S. Pavlov, Taisiia A. Turankova, Temesgen Tesfaye Ajabo, Leul Mekonnen Nigatu, Biniyam Esayas Dana, Poorani Gurumallesh Prabu. Predicting Clinically Significant Portal Hypertension in MASLD Using Routine Ultrasound and Clinical Data: A Retrospective Cohort Study. BioMed Research International 2026; 2026(1) doi: 10.1155/bmri/1662756
|
| 12 |
Akash Batta, Arka De, Omesh Goyal, Aalam Sohal. Editorial: The MASLD spectrum: an emerging epidemic of cardiometabolic and extra-hepatic dimensions. Frontiers in Epidemiology 2026; 6 doi: 10.3389/fepid.2026.1893613
|
| 13 |
Mario Romeo, Claudio Basile, Andrea Imperatore, Giambattista Mozzi, Fiammetta Di Nardo, Carmine Napolitano, Paolo Vaia, Luigi Di Puorto, Mattia Indipendente, Marcello Dallio, Alessandro Federico. Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Chronic Liver Diseases: Translating Mechanistic Insights into Clinical Practice and Future Perspectives. Cells 2026; 15(14) doi: 10.3390/cells15141292
|